HIV Diagnosis Jose-Luis Burgos, MD, AAHIVM Prevenmed-UCSD International Heath & Cross Cultural Medicine.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

HIV Counselling and Testing
Diagnosis and Management of Acute HIV Infection HIV Clinical Guidelines from the New York State Department of Health AIDS Institute January 2010 HIV CLINICAL.
Unit 6 Diagnosis & Follow-up of HIV Infection
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
GENERAL AWARENESS ON HIV/AIDS Presented by: WeHELP In Association with its MEDICAL TEAM.
D.Vijay kumar Dist.Sales Manager Abbott Hyderabad.
Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ
Genital Herpes Prevention and Clinical Services: What Should Health Departments Do Now? H. Hunter Handsfield, M.D. University of Washington Public Health.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
Version 11Page 1 of 6 Improving Identification of Patients Infected with HIV Using Rapid Testing in the Emergency Department: A Systems-Based Approach.
HIV Testing in Health-Care Settings
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
HIV PREVENTION EDUCATION By Stacie Brua RN, BSN.  HIV = Human Immunodeficiency Virus  HIV attacks the immune system, causing deficiency or damage in.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Diagnosis of HIV Infection
Hepatitis C Best Practice Guidelines Susan Thompson, RN, MPH September 2009.
HIV Testing in Health- Care Settings Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings U.S. Centers.
HIV Diagnosis, Acute Infection and Superinfection Don Kurtyka, ARNP, MS, MBA University of South Florida College of Medicine Tampa General Hospital Hillsborough.
Learning Objectives How to detect HIV antibodies/HIV infection?
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
HIV Testing CDC power point edited by M. Myers
Module 6: Routine HIV Testing of TB Patients. Learning Objectives Explain why TB suspects and patients should be routinely tested for HIV Summarize the.
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
HIV Testing Quality Assurance and Quality Control
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
HIV/AIDS Presented by Kunphen center for substance dependence and HIV/AIDS.
Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.
HIV Testing In Vermont Update 2007 Cathleen Harris, MD Fletcher Allen Health Care.
D-HIV Diagnosis, Acute Infection and Superinfection
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
HIV & AIDS What is it?.
Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Module II: Feeding and HIV Testing for Exposed Infants This module, we will discuss: Unit 1: Infant Feeding Guidelines Unit 2: HIV Testing and Treatment.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Diagnosis of AIDS Dr.T.V.Rao, MD..
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and.
SPECIAL CONSIDERATIONS August
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
New HIV Testing Requirements What Physicians Need to Know.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
CHRONIC VIRAL HEPATITIS CAUSES. HEPATITIS B Originally known as “serum hepatitis”. Percutaneous inoculation- long been recognized as the route of transmission.
Interventions for Clients with HIV/AIDS and Other Immunodeficiencies.
 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.
HIV & AIDS.
HIV/AIDS Minnesota Department of Education HIV/AIDS Prevention Program.
RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.
HIV and AIDS Quiz ANSWERS A Strategic Planning Session for Parliamentary Select Committees on HIV/AIDS and the Social Cluster Portfolio Committee. Maseru,
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
Developed by Theresa Allyn Based on Washington State HIV AIDS Curriculum Sponsored by the WSDA 1Copyright 2/2008.
California Clinical Laboratory Association
Hepatitis Primary Care: Clinics in Office Practice
INTEGRATING HIV AND HCV TESTING.
UNAIDS/WHO POLICY ON HIV TESTING June 2004
1985: First HIV-1 ELISA Approved by FDA
Diagnosis and Management of Acute HIV
Presentation transcript:

HIV Diagnosis Jose-Luis Burgos, MD, AAHIVM Prevenmed-UCSD International Heath & Cross Cultural Medicine

“Appearances to the mind are of four kinds. Things either are what the appear to be; or they neither are, nor appear to be; or they are, and do not appear to be; or they are not, yet appear to be. Rightly to aim in all these cases is the wise man’s task.” Epicteus, 2 nd Century A.D.

Objectives  Demonstrate knowledge about current HIV testing methods and interpretation of results  Ability to understand how a VCT program can prevent HIV transmission  Distinguish what tests are useful in infants  Identify rapid tests and their use in high risk and vulnerable population

1 mil 100,000 10,000 1, _ HIV RNA HIV-1 Antibodies Exposure P Symptoms Days HIV RNA Ab Typical Course of Primary HIV

Basic Principles of HIV testing  All persons receiving an HIV test should receive counseling for risk reduction before and after an HIV testing  Positive results need to be referred for initial evaluation.  HIV tests should be voluntary and with informed consent

 Many patients at highest risk for HIV have not been tested  Up to one third of patients receive their first HIV test within two months of an AIDS defining illness  40% of patients undergoing HIV testing do not return for results  ARV, Prevention of OI, effective interventions

Risk Assessment  Tuberculosis  Sexually transmitted disease  Behavioral risk factors –Sexual contact with commercial sex workers, injection drug users, multiple partners, MSM –Unprotected sex involving exchange of body fluids –Injection drug abuse –Blood product receipt (before reliable screening introduced)  In countries with generalized epidemics (e.g. South Africa), screening for HIV should be part of routine primary care

 Testing should be recommended for all pregnant women as soon as pregnancy is detected  Women with high risk for HIV infection, should have a repeat test during the third trimester  During labor, all women with unknown serologic status for HIV should be tested with the use of rapid tests  All exposed new born children should be tested between within 48 hours, months and 3-6 months. Risk Assessment

Anonymous vs Confidential  Anonymous –Identifying information not provided –Results not linked to identifying information –Allows reporting of HIV infection without breaching confidentiality –Disadvantage: may not be able to locate clients for test results  Confidential –Clients linked to test result by identifying information –Results remain confidential  Informed consent

Pre-Test Counseling  Goal: reduce HIV acquisition and transmission  Accurate and current information about HIV  Obtain informed consent  Transmission and acquisition  HIV test info: risk, benefits, meaning of potential test results  Assessment of individuals risks and appropriate risk reduction activities  Capacity to comprehend HIV testing and consent

Post-Test Counseling  Accurate and current information about HIV  Local resources  Risk reduction education  Referrals for ongoing care and support  Healthy living strategies  Meaning of test results and state reporting guidelines  Mental health support / counseling

Patient centered counseling  Talk with rather then to the patient  Individualize sessions (patients needs)  Neutral non-judgmental  Use open ended questions  Aim for a realistic risk-reduction plan  Offer options not directives  Recognize the counselor's limited role.

Diagnosis of HIV Infection  Viral antibodies  Viral antigens  Viral RNA/DNA  Culture Lancet, 1996; 348: 176.

Sensibility & Specificity Sensibility: Sensibility: Ability to identify infection in individuals that are truly infected. Ability to identify infection in individuals that are truly infected. Specificity: Specificity: Ability of the test to identify as negative individuals that are NOT infected Ability of the test to identify as negative individuals that are NOT infected

HIV Diagnostics  Approximate times to positivity* –1 st generation ELISA 42 days –3 rd generation ELISA23 days –p24 antigen assays16 days –RNA PCR11 days  95% seroconvert by 6 months  False positives –autoimmune disease, renal failure, cystic fibrosis, multiple pregnancies/transfusions, liver disease, post immunization  False negatives –window period, agammaglobulinemia, Group O, N, ± HIV-2 *Busch et al., Transfusion 1995;35:91-97

Negative Antibody Test Results  HIV negative  Recent infection: too early for seroconversion  CDC: follow-up testing at 6 weeks, 12 weeks, 6 months

Confirmation Process  Non-negative screenings should be confirmed –Western Blot (WB) –Immunofluorescent Antibody Assay (IFA)  Higher specificity than EIA  Interpretation can be subjective

IFA (Immunofluorescent Antibody Assay  Fluorognost HIV-1 IFA uses human material from infected T cells that express HIV-1 antigens. The cells are fixed to the surface of a glass slide, non infected cells are used as controls. When HIV antibodies are present in serum or plasma they attach to the infected cells but not to the non- infected cells.  Uses microscope, faster results

Western Blot  Detects antibodies to HIV-1 proteins –Core: p17, p24, p55 –Polymerase: p31, p51, p66 –Envelope: gp41, gp120, gp160  Negative: no bands  Positive: –Reactivity to gp41 + gp120/160 or –Reactivity to p24+gp120/160  Indeterminate: –EIA repeatedly reactive –Presence of any band pattern not meeting criteria for positive results

Predictive Value: HIV Ab Tests  Importance of pre-test probability in determining false + rate (Bayes theorem)  Depends on the prevalence of HIV infection in the population  Low HIV prevalence: predictive value of a positive test is low  HIV Ab testing of low prevalence populations likely to produce more false- positive than true-positive results

False Positive Results in Low vs. High Prevalence of HIV infection Prevalence in tested group Per 100,000 tests Number of false positives assuming 0.1 % prevalence Number of True Positives Ratio of False Positive/True Positives 1 in 100, :1 1 in 10, :1 1 in :1 1 in ,0001:10 1 in ,0001:100

Window Period  Time delay from infection to positive EIA –Average: days –Most seroconvert within six months Am J Med 2000; 109

False Negative Results  High-prevalence population: 0.3%  Low-prevalence: <0.001%  Usually due to testing during window period  Rare patients seroconvert in late- stage disease  Technical or clerical error  Type N or O  HIV-2

False Positive Test Results  Much less common than in earlier times –Frequency: % to %  Causes –Autoantibodies (single case, Lupus, ESRD) –HIV vaccines  EIA+: 68%  WB+: 0-44% –Technical / clerical error NEJM 1988;319:961 Ann Intern Med 1989;110:617

Indeterminate Results  4-20% of WB assays with positive bands  Testing during seroconversion –p24 usually appears first  Late stage HIV: loss of core antibody  HIV vaccine recipients  Technical / clerical error  Infection with O strain or HIV-2

Indeterminate Results (continued)  Cross-reacting nonspecific antibodies –Collagen-vascular disease –Autoimmune disease –Pregnancy –Organ transplantation –Lymphoma, other malignancies –Liver disease –Multiple sclerosis –Recent immunization

Indeterminate Results  Evaluate HIV risk  Low risk: almost never infected with HIV-1 or HIV-2 –Repeat testing: often continued indeterminate –Cause: frequently not established –HIV unlikely –Follow-up serology in 3 months  Seroconversion: usually WB+ in 1 month –Repeat testing at 1, 2, 6 months  Counseling to reduce potential transmission

Frequency of HIV Testing  High risk behavior: every 6-12 months  Annual seroconversion –General population: 0.02% –Military recruits: 0.04% –MSM: % –IDU in high prevalence area: 0.7-6%

Alternative Testing  Rapid Testing  Alternative body fluids –Saliva –Urine –Vaginal secretions  Viral detection  Home test kits

Rapid HIV Antibody Detection  Results in minutes  Occupational exposure  Women in labor with unknown HIV status  Clients unlikely to return for visits  Outreach  ERs

Rapid HIV Antibody Detection  OraQuick HIV-1 Antibody Test (OraSure) –Results read by provider in 20 minutes –Sensitivity: 99.6% / Specificity: 100% –$20-30  Fingerstick sample of blood  Negative test: definitive  Positive test: needs standard serology confirmation  Not recommended for HIV-2 screening

OraQuick Advance HIV-1/2  CLIA (Clinical Laboratory Improvement Amendment) waived for whole blood, saliva, plasma  Room temperature  Detects VIH-1/2  Results in 20 minutes

HIV 1/2 HIV 1/2

Stored Serum Phase II, Whole blood Phase II, plasma Phase III, whole blood Rapid test Se ns. Spec. Sens. Spe c. Sens.Spec.Sens.Spec. Determine 10 0% 98.0 % 100 % 100%100%100%99.9% MedMira Multispot *100* OraQuick OraQuick oral **98.9** SUDS *99.5* Unigold *Plasma specimens **Oral fluid specimens

Rapid Test Results  Reactive (preliminary positive) rapid test –Screening test is positive –Preliminary result –Confirmatory testing required –Precautions to avoid viral transmission  Negative rapid test –No recent exposure: definitive negative –Possible recent exposure:  Recommend re-test  Counseling to prevent transmission

P24 Antigen  Part of blood bank algorithms since 1996  Uncommon in clinical practice  Detects free, non-complex HIV antigens in peripheral blood

Indications for HIV Viral Detection  Confusing / indeterminate serologic test results  Acute retroviral infection  Neonatal infection  Window period following exposure  Not FDA approved for diagnosis of HIV  Expensive

Viral Detection  p24 Antigen  HIV-1 DNA PCR –Most sensitive: able to detect 1-10 copies of proviral DNA –S/S: 99% / 98%  HIV-1 RNA (RT-PCR, bDNA) –S/S: 95-98%  Viral culture of PBMC: expensive, labor intensive, reliability variable

 Recommendations for HIV Screening of Pregnant Women Universal testing for all pregnant women as a routine part of prenatal care using an “opt out” approach –Labor and Delivery: routine rapid testing if HIV status unknown –Postnatal: rapid testing for all infants whose mother’s status is unknown  Regulations, laws, and policies about HIV screening of pregnant women vary from state to state National Recommendations For HIV Testing of Pregnant Women

Diagnosis in Children < 18 months

DNA PCR DNA PCR (detects HIV proviral DNA within PBMC) Qualitative  Reactive  Non Reactive Sensitivity increases from 38% at birth to93% at 14 days at one mont S-S between % (Dunn 1995)

_

Detuned Antibody Testing  Less sensitive ELISA test  May help distinguish between recent seroconverters and those with long- standing HIV infection  Current ELISAs can detect relatively low levels of Ab  HIV Ab levels increase over first few months –Recent infection: standard ELISA positive –Detuned assay: negative  Able to diagnose individuals who have already seroconverted on a standard ELISA but are still early in infection

Recommended Websites  AIDSInfo website (  AETC National Resource Center   s.htm s.htm s.htm  

  “If we begin with certainties, we shall end in doubts; but if we begin with doubts, and are patient with them, we shall end with certainties” Sir Francis Bacon